Who is sponsoring NCT04123041?

NCT04123041 is sponsored by Juul Labs, Inc..

What drugs are being tested in NCT04123041?

Interventions in NCT04123041: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum.

What condition does NCT04123041 study?

NCT04123041 studies Electronic Cigarette Use, Tobacco Smoking.

Is NCT04123041 still recruiting?

NCT04123041 is currently completed. Last updated 13 February 2020.

Last reviewed 2020-02-13 · How we verify

NCT04123041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems

Completed NA Last updated 13 February 2020

What this trial tests

NA trial testing JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum in Electronic Cigarette Use in 137 participants. Completed in 18 December 2019.

Timeline

23 September 2019

Primary endpoint
18 December 2019

18 December 2019

Quick facts

Lead sponsor	Juul Labs, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	137
Start date	23 September 2019
Primary completion	18 December 2019
Estimated completion	18 December 2019
Sites	2 locations across United States

Drugs / interventions tested

JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum

Conditions studied

Electronic Cigarette Use — all drugs for Electronic Cigarette Use →
Tobacco Smoking — all drugs for Tobacco Smoking →

Sponsor

Juul Labs, Inc.

Who can join

Adults 21 to 65, any sex, with Electronic Cigarette Use or Tobacco Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to estimate nicotine uptake and assess subjective effects during ad libitum use sessions of 4 flavors of JUUL ENDS (also referred to as nicotine salt pod system; NSPS) products (i.e., Virginia Tobacco, Mint, Menthol and Mango) with 2 different nicotine concentrations. Subjective effects will also be assessed to gain an understanding of the user's experience during and after JUUL ENDS product use to evaluate the abuse liability of the products. The subject population will consist of healthy adult, male and female smokers, 21 to 65 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Electronic Cigarette Use

Currently open trials in the same condition.

NCT06609109 — Effect of Cannabis on E-Cigarette Use Behavior · Phase 1 · recruiting
NCT06610838 — Effects of E-cigarette Use on Health · recruiting
NCT04907136 — Developing and Testing Health Warning Labels on the ENDS Device · NA · recruiting
NCT06142877 — Effects of Social Media Use on Young Adults' E-Cigarette Use · NA · recruiting
NCT05338801 — Effect of Menthol on ENDS Users' Addiction and Exposure · NA · recruiting

Other Juul Labs, Inc. trials

Trials by the same sponsor.

NCT04088175 — Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-S · NA · completed
NCT04143256 — Evaluating Selected Constituents in the Exhaled Breath Samples · NA · completed
NCT04107779 — Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS · NA · completed
NCT03700112 — Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods. · NA · completed
NCT03719391 — United States Pre-Market Tobacco Application Pharmacokinetics · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04123041 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juul Labs, Inc.
Last refreshed: 13 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04123041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing